| 000 | 01123 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250514075227.0 | ||
| 264 | 0 | _c20030922 | |
| 008 | 200309s 0 0 eng d | ||
| 022 | _a0003-4967 | ||
| 024 | 7 |
_a10.1136/ard.62.9.793 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGladman, D D | |
| 245 | 0 | 0 |
_aEstablished criteria for disease controlling drugs in ankylosing spondylitis. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cSep 2003 |
||
| 300 |
_a793-4 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aSpondylitis, Ankylosing _xdrug therapy |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 62 _gno. 9 _gp. 793-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/ard.62.9.793 _zAvailable from publisher's website |
| 999 |
_c12695063 _d12695063 |
||